Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in J Invest Dermatol

Retrieve available abstracts of 106 articles:
HTML format



Single Articles


    January 2022
  1. CHU YS, Lee S, Lee SG, Chung KY, et al
    Deep Learning Algorithms for Predicting Breslow Thickness from Dermoscopic Images of Acral Lentiginous Melanomas.
    J Invest Dermatol. 2022 Jan 12. pii: S0022-202X(22)00008.
    PubMed    


  2. BUSTOS MA, Hoon DSB
    Prognostic Utility of CpG Island Hypermethylated Phenotype in Early-Stage Invasive Primary Melanomas.
    J Invest Dermatol. 2022 Jan 11. pii: S0022-202X(21)02629.
    PubMed     Abstract available


  3. MARCONI A, Quadri M, Farnetani F, Ciardo S, et al
    In Vivo Melanoma Cell Morphology Reflects Molecular Signature and Tumor Aggressiveness.
    J Invest Dermatol. 2022 Jan 7. pii: S0022-202X(21)02683.
    PubMed     Abstract available


  4. BECHMANN N, Calsina B, Richter S, Pietzsch J, et al
    Therapeutic Potential of Nitric Oxide releasing Selective Estrogen Receptor Modulators (NO-SERMs) in Malignant Melanoma.
    J Invest Dermatol. 2022 Jan 3. pii: S0022-202X(21)02691.
    PubMed     Abstract available


    December 2021
  5. KUMPER M, Hessenthaler S, Zamek J, Niland S, et al
    LOSS OF ENDOTHELIAL CELL MMP14 REDUCES MELANOMA GROWTH AND METASTASIS BY INCREASING TUMOR VESSEL STABILITY.
    J Invest Dermatol. 2021 Dec 27. pii: S0022-202X(21)02633.
    PubMed     Abstract available


  6. FANE ME, Chhabra Y, Spoerri L, Simmons JL, et al
    Reciprocal regulation of BRN2 and NOTCH1/2 signaling synergistically drives melanoma cell migration and invasion.
    J Invest Dermatol. 2021 Dec 24. pii: S0022-202X(21)02630.
    PubMed     Abstract available


  7. WANG Y, Ramachandran V, Sui D, Xu K, et al
    Evaluation of Plasma Interleukin-6 in Melanoma Patients as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker.
    J Invest Dermatol. 2021 Dec 21. pii: S0022-202X(21)02627.
    PubMed    


  8. MUKHERJEE N, Dart CR, Amato CM, Honig-Frand A, et al
    Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics.
    J Invest Dermatol. 2021 Dec 20. pii: S0022-202X(21)02617.
    PubMed     Abstract available


  9. KURTANSKY NR, Dusza SW, Halpern AC, Hartman RI, et al
    An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017.
    J Invest Dermatol. 2021 Dec 10. pii: S0022-202X(21)02610.
    PubMed     Abstract available


  10. HRISTOVA DM, Fukumoto T, Takemori C, Gao L, et al
    NUMB AS A NEW THERAPEUTIC TARGET FOR MELANOMA.
    J Invest Dermatol. 2021 Dec 6. pii: S0022-202X(21)02600.
    PubMed     Abstract available


  11. CHHABRA G, Ahmad N
    BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
    J Invest Dermatol. 2021 Dec 3. pii: S0022-202X(21)02485.
    PubMed     Abstract available


    November 2021
  12. CONWAY K, Tsai YS, Edmiston SN, Parker JS, et al
    Characterization of the CpG island hypermethylated phenotype (CIMP) subclass in primary melanomas.
    J Invest Dermatol. 2021 Nov 26. pii: S0022-202X(21)02531.
    PubMed     Abstract available


  13. LIYANAGE U, MacGregor S, Bishop DT, Shi J, et al
    Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma.
    J Invest Dermatol. 2021 Nov 20. pii: S0022-202X(21)02513.
    PubMed     Abstract available


  14. DEL ROSSO M, Fibbi G, Laurenzana A, Margheri F, et al
    A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy.
    J Invest Dermatol. 2021;141:2566-2568.
    PubMed     Abstract available


    October 2021
  15. DZUNG A, Saltari A, Tiso N, Lyck R, et al
    STK11 Prevents Invasion Through STAT3/5 and FAK Repression in Cutaneous Melanoma.
    J Invest Dermatol. 2021 Oct 29. pii: S0022-202X(21)02466.
    PubMed     Abstract available


  16. KIM RH, Nomikou S, Coudray N, Jour G, et al
    Deep learning and pathomics analyses reveal cell nuclei as important features for mutation prediction of BRAF-mutated melanomas.
    J Invest Dermatol. 2021 Oct 29. pii: S0022-202X(21)02405.
    PubMed     Abstract available


  17. KIURU M, Kriner MA, Wong S, Zhu G, et al
    High-plex spatial RNA profiling reveals cell type-specific biomarker expression during melanoma development.
    J Invest Dermatol. 2021 Oct 23. pii: S0022-202X(21)02370.
    PubMed     Abstract available


  18. AHMED F, Tseng HY, Ahn A, Gunatilake D, et al
    Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma.
    J Invest Dermatol. 2021 Oct 22. pii: S0022-202X(21)02384.
    PubMed     Abstract available


  19. NJAUW CN, Ji Z, Pham DM, Simoneau A, et al
    Oncogenic KIT Induces Replication stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma.
    J Invest Dermatol. 2021 Oct 20. pii: S0022-202X(21)02347.
    PubMed     Abstract available


  20. JANDOVA J, Wondrak GT
    Vemurafenib drives EMT gene expression in BRAFi-resistant BRAF(V600E)/NRAS(Q61K) melanoma enhancing tumor growth and metastasis in a bioluminescent murine model.
    J Invest Dermatol. 2021 Oct 20. pii: S0022-202X(21)02368.
    PubMed     Abstract available


  21. NAGORE E, Viros A, Kumar R
    Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma.
    J Invest Dermatol. 2021 Oct 16. pii: S0022-202X(21)02269.
    PubMed     Abstract available


  22. CHILIBROSTE S, Monaco A, Plata MC, Vola M, et al
    Preclinical evaluation of LVR01 attenuated Salmonella as neoadjuvant intralesional therapy in combination with chemotherapy for melanoma treatment.
    J Invest Dermatol. 2021 Oct 15. pii: S0022-202X(21)02317.
    PubMed     Abstract available


    September 2021
  23. CHHABRA G, Singh CK, Guzman-Perez G, Ndiaye MA, et al
    Anti-melanoma effects of concomitant inhibition of SIRT1 and SIRT3 in Braf(V600E)/Pten(NULL) mice.
    J Invest Dermatol. 2021 Sep 28. pii: S0022-202X(21)02223.
    PubMed     Abstract available


  24. XU T, Dai J, Tang L, Yang L, et al
    EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma.
    J Invest Dermatol. 2021 Sep 24. pii: S0022-202X(21)02227.
    PubMed     Abstract available


  25. EMMONS MF, Smalley KSM
    Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.
    J Invest Dermatol. 2021 Sep 23. pii: S0022-202X(21)01436.
    PubMed     Abstract available


  26. ADELMANN CH, Rachmin I, Fisher DE
    MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma.
    J Invest Dermatol. 2021 Sep 23. pii: S0022-202X(21)01224.
    PubMed     Abstract available


  27. GUTIERREZ-SEIJO A, Garcia-Martinez E, Barrio-Alonso C, Parra-Blanco V, et al
    Activin A sustains the metastatic phenotype of tumor associated macrophages and is a prognostic marker in human cutaneous melanoma.
    J Invest Dermatol. 2021 Sep 6. pii: S0022-202X(21)02171.
    PubMed     Abstract available


    August 2021
  28. DAS I, Tuominen R, Helleday T, Hansson J, et al
    Co-expression of MTH1 and PMS2 is associated with advanced disease and disease progression after therapy in melanoma.
    J Invest Dermatol. 2021 Aug 18. pii: S0022-202X(21)01689.
    PubMed    


  29. NARDIN C, Laheurte C, Puzenat E, Boullerot L, et al
    Naturally occurring Telomerase-specific CD4 T cell Immunity in Melanoma.
    J Invest Dermatol. 2021 Aug 2. pii: S0022-202X(21)01667.
    PubMed     Abstract available


    July 2021
  30. MONTAUDIE H, Sormani L, Dadone-Montaudie B, Heim M, et al
    CLEC12B decreases melanoma proliferation by repressing STAT3.
    J Invest Dermatol. 2021 Jul 23. pii: S0022-202X(21)01464.
    PubMed     Abstract available


  31. QUADRI M, Comitato A, Palazzo E, Tiso N, et al
    Activation of PKG restricts melanoma growth and invasion by interfering with the EGF/EGFR pathway.
    J Invest Dermatol. 2021 Jul 12. pii: S0022-202X(21)01420.
    PubMed     Abstract available


  32. WANG S, Yi X, Wu Z, Guo S, et al
    CAMKK2 defines ferroptosis sensitivity of melanoma cells by regulating AMPK-Nrf2 pathway.
    J Invest Dermatol. 2021 Jul 6. pii: S0022-202X(21)01416.
    PubMed     Abstract available


  33. PATMANATHAN SN, Tong BT, Jackie Teo JH, Jonathan Ting YZ, et al
    A PDZ Protein GIPC3 Positively Modulates Hedgehog Signaling and Melanoma Growth.
    J Invest Dermatol. 2021 Jul 2. pii: S0022-202X(21)01414.
    PubMed     Abstract available


  34. CHU EY, Takeshita J, Ming ME
    Shedding Light on Disparities in Melanoma Care.
    J Invest Dermatol. 2021;141:1625-1626.
    PubMed     Abstract available


    June 2021
  35. SHEINBOIM D, Parikh S, Parikh R, Menuchin A, et al
    Slow transcription of the 99a/let-7c/125b-2 cluster results in differential miRNA expression and promotes melanoma phenotypic plasticity.
    J Invest Dermatol. 2021 Jun 26. pii: S0022-202X(21)01406.
    PubMed     Abstract available


  36. KLEINERMAN RA, Schonfeld SJ, Abramson DH, Francis JH, et al
    Increased risk of skin cancer in 1851 long-term retinoblastoma survivors.
    J Invest Dermatol. 2021 Jun 18. pii: S0022-202X(21)01334.
    PubMed     Abstract available


    May 2021
  37. WANG H, Yi X, Guo S, Wang S, et al
    The XBP1-MARCH5-MFN2 axis confers ER stress resistance by coordinating mitochondrial fission and mitophagy in melanoma.
    J Invest Dermatol. 2021 May 25. pii: S0022-202X(21)01243.
    PubMed     Abstract available


  38. TSENG YJ, Lee CH, Chen WY, Yang JL, et al
    Inhibition of plasminogen activator inhibitor-1 blocks programmed death ligand 1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.
    J Invest Dermatol. 2021 May 14. pii: S0022-202X(21)01230.
    PubMed     Abstract available


  39. JI Z, Njauw CN, Guhan S, Kumar R, et al
    Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition.
    J Invest Dermatol. 2021;141:1317-1324.
    PubMed     Abstract available


    April 2021
  40. MUNIZ TP, Sorotsky H, Kanjanapan Y, Rose AAN, et al
    Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma.
    J Invest Dermatol. 2021 Apr 5. pii: S0022-202X(21)01132.
    PubMed     Abstract available


  41. DU-HARPUR X, Arthurs C, Ganier C, Woolf R, et al
    Clinically Relevant Vulnerabilities of Deep Machine Learning Systems for Skin Cancer Diagnosis.
    J Invest Dermatol. 2021;141:916-920.
    PubMed    


    March 2021
  42. HARBERS FN, Thier B, Stupia S, Zhu S, et al
    Melanoma differentiation trajectories determine sensitivity towards pre-existing CD8(+) tumor-infiltrating lymphocytes.
    J Invest Dermatol. 2021 Mar 30. pii: S0022-202X(21)01124.
    PubMed     Abstract available


  43. AL EMRAN A, Tseng HY, Gunatilake D, Cook SJ, et al
    A combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma.
    J Invest Dermatol. 2021 Mar 26. pii: S0022-202X(21)01121.
    PubMed     Abstract available


  44. GUHAN SM, Shaughnessy M, Rajadurai A, Taylor M, et al
    The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma.
    J Invest Dermatol. 2021 Mar 18. pii: S0022-202X(21)00977.
    PubMed     Abstract available


  45. PERES J, Damerell V, Chauhan J, Popovic A, et al
    TBX3 promotes melanoma migration by transcriptional activation of ID1 which prevents activation of E-cadherin by MITF.
    J Invest Dermatol. 2021 Mar 17. pii: S0022-202X(21)01001.
    PubMed     Abstract available


  46. MARCHETTI MA, Nanda JK, Mancebo SE, Dusza SW, et al
    Real-world application of a non-invasive 2-gene expression test for melanoma diagnosis.
    J Invest Dermatol. 2021 Mar 17. pii: S0022-202X(21)01018.
    PubMed    


  47. FREUND L, Kjaer SK, Guleria S, Albieri V, et al
    Use of fertility drugs and risk of malignant melanoma: results from a large Danish population-based cohort study.
    J Invest Dermatol. 2021 Mar 16. pii: S0022-202X(21)01022.
    PubMed     Abstract available


  48. TIKOO S, Jain R, Tomasetig F, On K, et al
    Amelanotic B16-F10 melanoma compatible with advanced 3-D imaging modalities.
    J Invest Dermatol. 2021 Mar 3. pii: S0022-202X(21)00156.
    PubMed    


    February 2021
  49. GRAMANN AK, Frantz WT, Dresser K, Ferreira Gomes CB, et al
    BMP signaling promotes neural crest identity and accelerates melanoma onset.
    J Invest Dermatol. 2021 Feb 18. pii: S0022-202X(21)00150.
    PubMed    


  50. KIM KB, Soroceanu L, de Semir D, Millis SZ, et al
    Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
    J Invest Dermatol. 2021 Feb 18. pii: S0022-202X(21)00155.
    PubMed     Abstract available


  51. KOIKOV L, Starner RJ, Swope VB, Upadhyay P, et al
    Development of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in Melanocytes.
    J Invest Dermatol. 2021 Feb 17. pii: S0022-202X(21)00117.
    PubMed     Abstract available


  52. SCHEEREN FA, van Doorn R
    Inhibition of the Epigenetic Reader BRD4 Reduces SIRPalpha-Mediated Phagocytosis and Melanoma Invasion.
    J Invest Dermatol. 2021;141:252-254.
    PubMed     Abstract available


  53. OSTROWSKI SM, Fisher DE
    The Melanocyte Lineage Factor miR-211 Promotes BRAF(V600E) Inhibitor Resistance.
    J Invest Dermatol. 2021;141:250-252.
    PubMed     Abstract available


    January 2021
  54. SHAH P, Shao Y, Geller AC, Polsky D, et al
    Late stage melanoma in New York State: associations with socioeconomic factors and healthcare access at the county level.
    J Invest Dermatol. 2021 Jan 28. pii: S0022-202X(21)00031.
    PubMed     Abstract available


  55. YU WY, Hill ST, Chan ER, Pink JJ, et al
    Computational drug repositioning identifies statins as a modifier of prognostic genetic expression signatures and metastatic behavior in melanoma.
    J Invest Dermatol. 2021 Jan 5. pii: S0022-202X(20)32413.
    PubMed     Abstract available


  56. ZHOU Q, Kim SH, Perez-Lorenzo R, Liu C, et al
    Phenformin Promotes Keratinocyte Differentiation via the Calcineurin/NFAT Pathway.
    J Invest Dermatol. 2021;141:152-163.
    PubMed     Abstract available


    December 2020
  57. TRAVNICKOVA J, Patton EE
    Deciphering melanoma cell states and plasticity with zebrafish models.
    J Invest Dermatol. 2020 Dec 16. pii: S0022-202X(20)32400.
    PubMed     Abstract available


  58. FUKUMOTO T, Lin J, Fatkhutdinov N, Liu P, et al
    ARID2 deficiency correlates with the response to immune checkpoint blockade in melanoma.
    J Invest Dermatol. 2020 Dec 14. pii: S0022-202X(20)32396.
    PubMed     Abstract available


    November 2020
  59. DOEPNER M, Lee IY, Ridky TW
    Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis.
    J Invest Dermatol. 2020;140:2114-2116.
    PubMed     Abstract available


    October 2020
  60. POIZEAU F, Kerbrat S, Happe A, Rault C, et al
    Patients with metastatic melanoma receiving anticancer drugs: changes in overall survival, 2010-2017.
    J Invest Dermatol. 2020 Oct 10. pii: S0022-202X(20)32138.
    PubMed     Abstract available


    September 2020
  61. OLSEN CM, Pandeya N, Dusingize JC, Thompson BS, et al
    Can people correctly assess their future risk of melanoma?
    J Invest Dermatol. 2020 Sep 11. pii: S0022-202X(20)31964.
    PubMed    


  62. ZHANG C, Smalley I, Emmons MF, Sharma R, et al
    Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma.
    J Invest Dermatol. 2020 Sep 2. pii: S0022-202X(20)32047.
    PubMed     Abstract available


  63. CORNELIUS LA
    The Melanoma JID Connector Collection: An Introduction.
    J Invest Dermatol. 2020;140:1690.
    PubMed    


  64. LEE B, Sahoo A, Sawada J, Marchica J, et al
    MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAF(V600E)-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance.
    J Invest Dermatol. 2020 Sep 1. pii: S0022-202X(20)32043.
    PubMed     Abstract available


  65. HUANG SW, Wang ST, Chang SH, Chuang KC, et al
    Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
    J Invest Dermatol. 2020;140:1771-1783.
    PubMed     Abstract available


    August 2020
  66. SWAMINATHAN K, Campbell A, Papalazarou V, Jaber-Hijazi F, et al
    The RAC1 target NCKAP1 plays a crucial role in progression of BRAF/PTEN -driven melanoma in mice.
    J Invest Dermatol. 2020 Aug 7. pii: S0022-202X(20)31956.
    PubMed     Abstract available


  67. RODGERS CB, Broit N, Johansson PA, Pritchard AL, et al
    Attack of the Subclones: Accurate Detection of Mutational Heterogeneity in Bulk DNA from Tumors.
    J Invest Dermatol. 2020;140:1501-1503.
    PubMed     Abstract available


  68. QUAN VL, Zhang B, Zhang Y, Mohan LS, et al
    Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
    J Invest Dermatol. 2020;140:1599-1608.
    PubMed     Abstract available


    July 2020
  69. LE K, Matar H, Gupta M
    Bromodomain epigenetic protein promotes metastatic potential in melanoma cells via increased invasiveness and decreased macrophage-mediated phagocytosis.
    J Invest Dermatol. 2020 Jul 6. pii: S0022-202X(20)31733.
    PubMed    


  70. TETZLAFF MT, Farah M
    Without Missing a Beat: Absence of Cilia Informs the Diagnosis of Histopathologically Challenging Spitzoid Melanocytic Neoplasms.
    J Invest Dermatol. 2020;140:1320-1323.
    PubMed     Abstract available


    June 2020
  71. WANG P, Li Y, Ma Y, Zhang X, et al
    Comprehensive investigation into the role of ubiquitin conjugating enzyme E2S (UBE2S) in melanoma development.
    J Invest Dermatol. 2020 Jun 27. pii: S0022-202X(20)31729.
    PubMed     Abstract available


  72. RAHMAN H, Kumar D, Liu T, Okwundu N, et al
    Aspirin protects melanocytes and keratinocytes against UVB-induced DNA damage in vivo.
    J Invest Dermatol. 2020 Jun 19. pii: S0022-202X(20)31684.
    PubMed     Abstract available


    May 2020
  73. TRUCCO LD, Mundra PA, Garcia-Martinez P, Hogan K, et al
    Map3k1 Loss Cooperates With Braf(V600E) to Drive Melanomagenesis.
    J Invest Dermatol. 2020 May 22. pii: S0022-202X(20)31598.
    PubMed    


  74. NGUYEN MQ, Teh JLF, Purwin TJ, Chervoneva I, et al
    Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition.
    J Invest Dermatol. 2020 May 7. pii: S0022-202X(20)31406.
    PubMed     Abstract available


  75. ADAM C, Fusi L, Weiss N, Goller SG, et al
    Efficient suppression of NRAS-driven melanoma by co-inhibition of ERK1/2 and ERK5 MAPK pathways.
    J Invest Dermatol. 2020 May 3. pii: S0022-202X(20)31407.
    PubMed     Abstract available


    April 2020
  76. AVITAN-HERSH E, Feng Y, Vaisman AO, Ahmed YA, et al
    Regulation of eIF2alpha by RNF4 promotes melanoma tumorigenesis and therapy resistance.
    J Invest Dermatol. 2020 Apr 29. pii: S0022-202X(20)31404.
    PubMed     Abstract available


  77. TIFFEN J, Gallagher S, Filipp F, Gunatilake D, et al
    EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma.
    J Invest Dermatol. 2020 Apr 29. pii: S0022-202X(20)31390.
    PubMed     Abstract available


  78. CHAVEZ A, Quesenberry CP Jr, Darbinian J, Asgari MM, et al
    Association of valproic acid use, a potent histone deacetylase inhibitor, and melanoma risk.
    J Invest Dermatol. 2020 Apr 27. pii: S0022-202X(20)31402.
    PubMed     Abstract available


  79. GUO Y, Zhang X, Zeng W, Zhang J, et al
    TRAF6 activates fibroblasts to cancer-associated fibroblasts (CAFs) through FGF19 in tumor microenvironment to benefit the malignant phenotype of melanoma cells.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31352.
    PubMed     Abstract available


  80. KUNG FF, Arias-Mejias SM, Quattrocchi E, Sominidi-Damodaran S, et al
    PD-1, PD-L1 and BIM as predictors of sentinel lymph node metastasis in primary cutaneous melanoma.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31349.
    PubMed    


  81. DIKA E, Riefolo M, Porcellini E, Broseghini E, et al
    Defining the prognostic role of microRNAs in cutaneous melanoma.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31351.
    PubMed     Abstract available


  82. JENKINS RW, Fisher DE
    Treatment of Advanced Melanoma in 2020 and Beyond.
    J Invest Dermatol. 2020 Apr 5. pii: S0022-202X(20)31257.
    PubMed     Abstract available


  83. JOSHI SS, Hornyak TJ
    Cellular Phenotypic Plasticity of Cutaneous Melanoma: A Complex Puzzle.
    J Invest Dermatol. 2020;140:743-745.
    PubMed     Abstract available


  84. HALSE H, Caramia F, McLean CA, Wang M, et al
    A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response.
    J Invest Dermatol. 2020;140:869-877.
    PubMed     Abstract available


    March 2020
  85. CHRISTODOULOU E, Nell RJ, Verdijk RM, Gruis NA, et al
    Loss of wild-type CDKN2A is an early event in the development of melanoma in FAMMM syndrome.
    J Invest Dermatol. 2020 Mar 28. pii: S0022-202X(20)31205.
    PubMed    


  86. KIM E, Panzella L, Napolitano A, Payne GF, et al
    Redox Activities of Melanins Investigated by Electrochemical Reverse Engineering: Implications for their Roles in Oxidative Stress.
    J Invest Dermatol. 2020;140:537-543.
    PubMed     Abstract available


    February 2020
  87. VESELY MD, Chen L
    Normalization Cancer Immunotherapy for Melanoma.
    J Invest Dermatol. 2020 Feb 21. pii: S0022-202X(20)30153.
    PubMed     Abstract available


  88. CHANG GA, Wiggins JM, Corless BC, Syeda MM, et al
    TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors.
    J Invest Dermatol. 2020 Feb 19. pii: S0022-202X(20)30159.
    PubMed     Abstract available


  89. PATEL S, Wilkinson CJ, Sviderskaya EV
    Loss of both CDKN2A and CDKN2B allows for centrosome overduplication in melanoma.
    J Invest Dermatol. 2020 Feb 14. pii: S0022-202X(20)30147.
    PubMed     Abstract available


    January 2020
  90. GUO D, Jain R, Hwang JS, Weninger W, et al
    RAB27A/Melanophilin blocker inhibits melanoma cell motility and invasion.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30036.
    PubMed    


  91. LANG UE, Torres R, Cheung C, Vladar EK, et al
    Ciliation index is a useful diagnostic tool in challenging spitzoid melanocytic neoplasms.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30038.
    PubMed     Abstract available


  92. BRAUN AD, Mengoni M, Bonifatius S, Tuting T, et al
    Activated Hgf-Met signaling cooperates with oncogenic Braf to drive primary cutaneous melanomas and angiotropic lung metastases in mice.
    J Invest Dermatol. 2020 Jan 20. pii: S0022-202X(20)30019.
    PubMed     Abstract available


  93. HONG CH, Ho JC, Lee CH
    Steroid receptor RNA activator (SRA), a long noncoding RNA, activates p38, facilitates epithelial mesenchymal transformation, and experimental melanoma metastasis.
    J Invest Dermatol. 2020 Jan 13. pii: S0022-202X(19)33503.
    PubMed     Abstract available


  94. SHELLMAN MH, Shellman YG
    Human against Machine? Machine Learning Identifies MicroRNA Ratios as Biomarkers for Melanoma.
    J Invest Dermatol. 2020;140:18-20.
    PubMed     Abstract available


    December 2019
  95. CHITSAZAN A, Lambie D, Ferguson B, Handoko HY, et al
    Unexpected High Levels of BRN2/POU3F2 Expression in Human Dermal Melanocytic Nevi.
    J Invest Dermatol. 2019 Dec 24. pii: S0022-202X(19)33492.
    PubMed    


  96. BARCELO C, Siso P, Maiques O, Garcia-Mulero S, et al
    T-Type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAF(V600E) melanoma: TTCCs are therapy target in BRAF(V600E) melanoma.
    J Invest Dermatol. 2019 Dec 23. pii: S0022-202X(19)33497.
    PubMed     Abstract available


    November 2019
  97. LIU X, Mi J, Qin H, Li Z, et al
    E2F1/IGF-1R loop contributes to BRAF inhibitor resistance in melanoma.
    J Invest Dermatol. 2019 Nov 6. pii: S0022-202X(19)33385.
    PubMed    


    October 2019
  98. WENZINA J, Holzner S, Puujalka E, Cheng PF, et al
    Inhibition of p38/MK2 signaling prevents vascular invasion of melanoma.
    J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)33299.
    PubMed     Abstract available


  99. ZENG H, Judson-Torres RL, Shain AH
    The Evolution of Melanoma - Moving beyond Binary Models of Genetic Progression.
    J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)32699.
    PubMed     Abstract available


    September 2019
  100. GIBBS DC, Orlow I, Vernali S, Powell HB, et al
    Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma.
    J Invest Dermatol. 2019 Sep 27. pii: S0022-202X(19)33239.
    PubMed    


    August 2019
  101. TORRES R, Lang UE, Hejna M, Shelton SJ, et al
    MicroRNA ratios distinguish melanomas from nevi.
    J Invest Dermatol. 2019 Aug 22. pii: S0022-202X(19)31788.
    PubMed     Abstract available


    July 2019
  102. PEI S, Chen J, Lu J, Hu S, et al
    The Long Noncoding RNA UCA1 Negatively Regulates Melanogenesis in Melanocytes.
    J Invest Dermatol. 2019 Jul 2. pii: S0022-202X(19)31848.
    PubMed     Abstract available


    March 2019
  103. TAKABE P, Karna R, Rauhala L, Tammi M, et al
    Melanocyte hyaluronan coat fragmentation enhances the UVB-induced TLR-4 receptor signaling and expression of proinflammatory mediators IL-6, IL-8, CXCL-1 and CXCL-10 via NF-kappaB activation.
    J Invest Dermatol. 2019 Mar 29. pii: S0022-202X(19)31391.
    PubMed     Abstract available


    January 2019
  104. SHIN SY, Choi JH, Jung E, Gil HN, et al
    The EGR1-STAT3 Transcription Factor Axis Regulates alpha-MSH-induced Tyrosinase Gene Transcription in Melanocytes.
    J Invest Dermatol. 2019 Jan 12. pii: S0022-202X(19)30010.
    PubMed    


  105. AVIGAD LARON E, Aamar E, Enshell-Seijffers D
    The Serine Protease Activity of Corin Is Required for Normal Pigment Type Switching.
    J Invest Dermatol. 2019;139:257-259.
    PubMed    


    July 2018
  106. ZHANG K, Anumanthan G, Scheaffer S, Cornelius LA, et al
    HMGB1/RAGE Mediates UVB-induced Secretory Inflammatory Response and Resistance to Apoptosis in Human Melanocytes.
    J Invest Dermatol. 2018 Jul 17. pii: S0022-202X(18)32348.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: